Teva secures $400 million from Blackstone to advance flagship IBD drug
The funding bolsters late-stage development of Duvakitug as the company races toward a $30 billion market.
Teva is securing additional capital to advance the development of Duvakitug, its most promising experimental treatment for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease.
Teva will receive $400 million over four years from Blackstone through its life sciences investment arm, Blackstone Life Sciences (BXLS). The funding is designed to support the continued clinical development of the drug as it moves through late-stage trials.
Under the terms of the agreement, BXLS will be entitled to regulatory and commercial milestone payments if the drug receives approval from the U.S. Food and Drug Administration, as well as single-digit royalties on global sales.
The deal marks the second major partnership Teva has signed to accelerate Duvakitug’s development in an effort to outpace competitors in a market estimated at nearly $30 billion annually. In 2023, Teva entered into a separate $1.5 billion agreement with Sanofi to support the program.
Duvakitug targets the TL1A pathway, a mechanism increasingly viewed as promising in the treatment of inflammatory bowel diseases. Teva has reported what it describes as the strongest results to date in Phase II clinical trials for this class of therapy and is currently conducting a pivotal Phase III study. Two weeks ago, the company released additional data indicating sustained efficacy in ongoing trials.
